Introduction: To investigate the role of tumor galectin-1 and galectin-3 in patients with lung adenocarcinoma after definitive radiation therapy.
Methods: A total of 41 patients with localized lung adenocarcinoma undergoing thoracic radiation therapy without concurrent chemotherapy were enrolled. Their paraffin-embedded lung tissues were sent for immunohistochemical staining for galectin-1 and galectin-3. The clinical treatment outcomes, including overall (OS), locoregional progression-free (LRPFS), and distant metastasis-free (DMFS) survivals, were evaluated. Univariable and multivariable Cox regression analyses were applied.
Results: Overexpression of tumor galectin-1 and galectin-3 were found in 26.8% and 19.5% of patients, respectively. Overexpression of tumor galectin-1 was the most significant prognosticator to predict worse LRPFS in both univariable ( = 0.007) and multivariable analyses ( = 0.022). Besides, patients with overexpression of tumor galectin-1 had a trend of worse OS ( = 0.066) than those with low expression in multivariable analysis, and worse DMFS ( = 0.035) in univariable analysis. The overexpression of tumor galectin-3 had no significant effect on survival outcomes.
Conclusions: The overexpression of tumor galectin-1, but not galectin-3, is associated with poor LRPFS of patients with lung adenocarcinoma after thoracic radiation therapy. Future research on the mechanism of galectin-1 affecting radiation response in lung adenocarcinoma may be worth exploring.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8904358 | PMC |
http://dx.doi.org/10.3389/fonc.2022.834749 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!